Biochemical Pharmacology volume 80, issue 5, P613-623 2010 DOI: 10.1016/j.bcp.2010.05.014 View full text
|
|
Share
Takeshi Yoshida, Guolin Zhang, Eric B. Haura

Abstract: Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide. Platinum-based doublets remain the current standard therapy for advanced NSCLC. However, overall survival (OS) has reached a plateau, even with the improvement in these regimens. Advances in the knowledge of molecular mechanisms of carcinogenesis have prompted the development of many novel molecular-targeted agents including the epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). Results of the recent ph…

expand abstract